Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
MHRA publishes final Business Plan for 2023-2026 Corporate Plan
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
Medical devices: conformity assessment and the UKCA mark
How to conform with the legal requirements for placing medical devices on the market.
Standard: Statement of Policy Intent: Early Access to Innovative Medical Devices
The MHRA’s initial plans on an Early Access service, which will be developed further throughout 2025.
MHRA seizes 7.7 million doses of illegal medicines and removes hundreds of illegal online listings as part of Operation Pangea
Operation Pangea brings together health regulators, customs authorities, law enforcement agencies, and private sector partners to tackle the threat posed by global criminal networks
Guidance: Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) is focused on getting the most transformative new medicines to patients in the UK health system more quickly.